Tag: Madrigal pharmaceuticals

The list price for Rezdiffra, the first and only FDA-approved medication for MASH, is approximately $47,400 per year. However, the amount patients actually pay can vary significantly based on their insurance coverage, eligibility for financial assistance, and other factors.

As the first and only FDA-approved medication for MASH, Rezdiffra is available exclusively through a limited specialty pharmacy network, not from standard retail drugstores. This means patients prescribed Rezdiffra must go through a specific process involving their healthcare provider and the manufacturer's patient support program to access their medication.

With a wholesale acquisition cost of approximately $47,400 per year, Rezdiffra's price point has drawn significant attention. The question 'Why is Rezdiffra so expensive?' is answered by several factors, including its status as the first-in-class treatment for MASH, extensive research and development costs, and market exclusivity.

In March 2024, Rezdiffra (resmetirom) became the first FDA-approved medication specifically for noncirrhotic non-alcoholic steatohepatitis (NASH), now known as MASH. This landmark approval was a significant development for patients and healthcare providers, yet it has raised a critical question: is there a generic for Rezdiffra? The short answer is no, and its status as a brand-name-only medication is tied to complex legal and commercial factors.

Following its FDA accelerated approval in March 2024, Rezdiffra™ (resmetirom) became the first and only medication specifically approved for treating noncirrhotic nonalcoholic steatohepatitis (NASH). As a specialized treatment, Rezdiffra™ is not available at standard retail pharmacies, and obtaining it requires a specific process involving a prescription and a network of specialty pharmacies.